Replies to post #54870 on Biotech Values

[DewDiligence]

If some NSTK longs think PG is going to make a buyout bid, they’re badly mistaken, IMO.

PFE never dropped COLY’s cancer drug even though the phase-3 trials in NSCLC failed. PG, on the other hand, wants nothing whatsoever to do with NSTK’s intranasal PTH (or intranasal anything for that matter).

[DewDiligence]

>…fleeing partners are only really fleeing to reduce the stock price so they can buy the company later.<

I waiting for Mr. Croumagnon to weigh in on this one.

[rkrw]

Actually Pfizer never dropped the partnership, contrary they seemed to be expanding and even nominated a new compound 2 weeks ago. So Pfizer didn't flee and coly went down for good reason, their seminal trial was a bust. So maybe the truth is the opposite, pfizer sticking around and reupping was a good sign.